1077 related articles for article (PubMed ID: 20719300)
1. Polypoidal choroidal vasculopathy masquerading as neovascular age-related macular degeneration refractory to ranibizumab.
Stangos AN; Gandhi JS; Nair-Sahni J; Heimann H; Pournaras CJ; Harding SP
Am J Ophthalmol; 2010 Nov; 150(5):666-73. PubMed ID: 20719300
[TBL] [Abstract][Full Text] [Related]
2. Improvement of angiographic findings of polypoidal choroidal vasculopathy after intravitreal injection of ranibizumab monthly for 3 months.
Hikichi T; Ohtsuka H; Higuchi M; Matsushita T; Ariga H; Kosaka S; Matsushita R; Takami K
Am J Ophthalmol; 2010 Nov; 150(5):674-682.e1. PubMed ID: 20691424
[TBL] [Abstract][Full Text] [Related]
3. Angiographic and optical coherence tomographic results of the MARINA study of ranibizumab in neovascular age-related macular degeneration.
Kaiser PK; Blodi BA; Shapiro H; Acharya NR;
Ophthalmology; 2007 Oct; 114(10):1868-75. PubMed ID: 17628683
[TBL] [Abstract][Full Text] [Related]
4. Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy.
Lai TY; Lee GK; Luk FO; Lam DS
Retina; 2011 Sep; 31(8):1581-8. PubMed ID: 21610566
[TBL] [Abstract][Full Text] [Related]
5. Choroidal thickness in polypoidal choroidal vasculopathy and exudative age-related macular degeneration.
Chung SE; Kang SW; Lee JH; Kim YT
Ophthalmology; 2011 May; 118(5):840-5. PubMed ID: 21211846
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy.
Wakabayashi T; Gomi F; Sawa M; Tsujikawa M; Nishida K
Br J Ophthalmol; 2012 Mar; 96(3):394-9. PubMed ID: 21719568
[TBL] [Abstract][Full Text] [Related]
7. Correlation of indocyanine green angiography and optical coherence tomography findings after intravitreal ranibizumab for polypoidal choroidal vasculopathy.
Ueno C; Gomi F; Sawa M; Nishida K
Retina; 2012; 32(10):2006-13. PubMed ID: 22772392
[TBL] [Abstract][Full Text] [Related]
8. Elevated C-reactive protein levels in patients with polypoidal choroidal vasculopathy and patients with neovascular age-related macular degeneration.
Kikuchi M; Nakamura M; Ishikawa K; Suzuki T; Nishihara H; Yamakoshi T; Nishio K; Taki K; Niwa T; Hamajima N; Terasaki H
Ophthalmology; 2007 Sep; 114(9):1722-7. PubMed ID: 17400294
[TBL] [Abstract][Full Text] [Related]
9. Intravitreal ranibizumab for polypoidal choroidal vasculopathy with recurrent or residual exudation.
Saito M; Iida T; Kano M
Retina; 2011 Sep; 31(8):1589-97. PubMed ID: 21654347
[TBL] [Abstract][Full Text] [Related]
10. Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy.
Cho M; Barbazetto IA; Freund KB
Am J Ophthalmol; 2009 Jul; 148(1):70-8.e1. PubMed ID: 19403115
[TBL] [Abstract][Full Text] [Related]
11. One-year outcomes of intravitreal bevacizumab (avastin) therapy for polypoidal choroidal vasculopathy.
Cheng CK; Peng CH; Chang CK; Hu CC; Chen LJ
Retina; 2011 May; 31(5):846-56. PubMed ID: 21317837
[TBL] [Abstract][Full Text] [Related]
12. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
Fung AE; Lalwani GA; Rosenfeld PJ; Dubovy SR; Michels S; Feuer WJ; Puliafito CA; Davis JL; Flynn HW; Esquiabro M
Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
[TBL] [Abstract][Full Text] [Related]
13. Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy.
Ricci F; Calabrese A; Regine F; Missiroli F; Ciardella AP
Retina; 2012 Jul; 32(7):1280-8. PubMed ID: 22218148
[TBL] [Abstract][Full Text] [Related]
14. Two-year course of subfoveal pigment epithelial detachment in eyes with age-related macular degeneration and visual acuity better than 20/40.
Baba T; Kitahashi M; Kubota-Taniai M; Oshitari T; Yamamoto S
Ophthalmologica; 2012; 228(2):102-9. PubMed ID: 22508168
[TBL] [Abstract][Full Text] [Related]
15. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
Arias L; Ruiz-Moreno JM; Gómez-Ulla F; Fernández M; Montero J
Retina; 2009; 29(10):1444-9. PubMed ID: 19730163
[TBL] [Abstract][Full Text] [Related]
16. Polypoidal choroidal vasculopathy and late geographic hyperfluorescence on indocyanine green angiography.
Kang SW; Chung SE; Shin WJ; Lee JH
Br J Ophthalmol; 2009 Jun; 93(6):759-64. PubMed ID: 19304584
[TBL] [Abstract][Full Text] [Related]
17. [Polypoidal choroidal vasculopathy--a rare form of choroidal neovascularization].
Weglarz M; Karska-Basta I; Kubicka-Trzaska A; Romanowska-Dixon B
Klin Oczna; 2009; 111(4-6):145-8. PubMed ID: 19673446
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of intravitreal bevacizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy.
Gomi F; Sawa M; Wakabayashi T; Sasamoto Y; Suzuki M; Tsujikawa M
Am J Ophthalmol; 2010 Jul; 150(1):48-54.e1. PubMed ID: 20609707
[TBL] [Abstract][Full Text] [Related]
19. One-year results of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy.
Song MH; Ryu HW; Roh YJ
Ophthalmologica; 2011; 226(3):119-26. PubMed ID: 21757883
[TBL] [Abstract][Full Text] [Related]
20. Polypoidal choroidal vasculopathy: an angiographic discussion.
Lim TH; Laude A; Tan CS
Eye (Lond); 2010 Mar; 24(3):483-90. PubMed ID: 20075967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]